Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.

A group of expert researchers from Strategic Market Research have elucidated that the Market for Human Microbiome was USD 88.06 million in 2020 & is likely to reach a substantial landmark of nearly USD 1318.72 million in 2030 with a robust CAGR value of around 31.08%. Let us make you acquainted with the pivotal statistics provided below.

Sambalpur, INDIA

New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms have a major impact on human physiology, thereby contributing to the enhancement or impairment of various immune and metabolic functions. The major factors that are promoting the growth of the Global Human Microbiome Market are the continuous increase in Industry-Institute Partnerships, rise in the number of lifestyle diseases, growing technological advancements in metagenomics, and rising focus on human Microbiome therapies, and next-generation sequencing. In terms of Application, the Therapeutics segment led the market growth in 2020 with a share of around 67.14% & based on region, North America comprehensively held the largest market share of around 41.22%. However, the Asia-Pacific region was regarded as the fastest-growing segment with a robust CAGR value.

To get a first-hand overview of the report, Request a Sample at

The report published by Strategic Market Research on Human Microbiome Market is segmented based on:


  • Prebiotics
  • Probiotics
  • Medical Foods
  • Drugs


  • Diagnostics
  • Therapeutics

Disease Type

  • Metabolic
  • Infectious
  • Endocrine 


North America


· Mexico

· Canada

· Rest of North America


· Germany

· France

· Russia

· Switzerland

· U.K

· Finland

· Turkey

· Netherlands 

· Belgium

· Spain

· Italy

· Rest of Europe

Asia Pacific

· China

· India

· Indonesia

· Thailand

· Japan

· South Korea

· Singapore

· Malaysia

· Philippines

· Australia

· New Zealand

· Rest of APAC


· Brazil

· Saudi Arabia

· Uruguay

· Argentina

· Rest of LAMEA

Make a Direct Purchase of the latest Human Microbiome Market Report published in the month of December 2021. Click the below link to initiate the purchase:

Key factors propelling the Market Growth:

  • The crucial factors that are responsible for the propulsion of the Global Human Microbiome Market growth are the continuous rise in the number of lifestyle diseases, increase in the focus on human Microbiome therapies, rapidly growing technological advancements in next-generation sequencing and metagenomics, etc. The Cleveland Clinic has stated that almost 80% of the chronic diseases that occur globally are driven by the lifestyle factors such as dieting & exercising. Also, Lifestyle diseases have affected approximately 75 % of the total population across the globe.

  • Apart from these, some of the crucial factors include a rise in the usage of Lightweight materials to improve safety & efficiency and the continuing trend of self-cleaning technologies.

In terms of Product, the ‘Drugs segment dominated the market in all respects. 

In terms of Product, the market is fragmented into Prebiotics, Probiotics, Medical Foods, & Drugs. The ‘Drugs’ segment comprehensively dominated the market with a total share of almost 52.14% in 2020. The rising number of human microbiome-based therapeutic products in the clinical trials along with increased funding to develop microbiome-based medications are augmenting the segment growth widely throughout the estimated period of 2020-2030. NCBI had delineated that the human microbiota, is composed of 10-100 trillion symbiotic microbial cells that reside in each person & play a pivotal role in the betterment of human health.

Based On Application, the Therapeutics segment held the maximum share of the market in 2020

For Application, the market has been segmented into Therapeutics and Diagnostics. The ' Therapeutics ' segment significantly held the largest market share of around 67.14%. Therapeutic manipulation of the human microbiome is regarded as a rapidly advancing field, and these treatments are capable of reversing a damaged, dysbiotic microbiome and are also highly effective in managing certain human diseases. All of these factors are enhancing the growth of this segment across the globe. As per INTERGRIS Health, dysbiotic microbiomes respond quickly to a change in diet, and the lifespan of a microbe exists for only 20 minutes.

On the other hand, the ‘Diagnostics segment held the fastest growth rate from 2020-to 2030 due to the rise of scientific & technological innovations in human genome mapping & the emergence of omics technologies. 

By Disease Type, the ‘Infectious’ segment held the largest share of the market in 2020.

In terms of Disease Type, the market has been ramified into Metabolic, Infectious, and Endocrine. The 'Infectious' segment held the most significant proportion of the market share in 2020. The vital factors that are accelerating the growth of this segment are the rise in the need for specific bacterial-targeted therapy for infectious diseases, the rising incidence of infections due to scarcity of antibiotic treatments, & the increase in the number of clinical trials for target-specific microbiome-based therapies. The World Health Organization has declared that infectious diseases have become one of the major factors of all mortalities that occur worldwide. Infectious diseases kill around 17 million people per year across the globe.

North America continued to dominate the Human Microbiome market:-

Based on Region, North America dominated the market in all respects with a share of almost 41.22% & is likely to continue its era of dominance throughout the forecasted frame of time. The prevalence of highly advanced healthcare facilities and increased investment from the major players in the healthcare sector is fuelling the market growth in this region. The Center for Medicare & Medicaid services asserted that the expenditure on the health care sector in the United States grew by 9.7 percent in 2020, reaching a staggering amount of USD 4.1 trillion or USD 12,530 per person. Also the health expenditure in USA accounted for up to 19.7 percent of the total share of the nation's Gross Domestic Product.

On the other hand, the APAC or Asia Pacific region showed the fastest rate of growth with a robust CAGR due to better rising awareness, a rise in medical tourism, an increase in government initiatives, and a substantial rise in funding for R&D activities, etc. 

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report

List of key players that are prevailing in the Human Microbiome Market worldwide:

  • AOBiome
  • Seres Therapeutics
  • 4D Pharma
  • Enterome Biosciences SA
  • Metabiomics Corp. (BioSpherex LLC)
  • Microbiome Therapeutics LLC
  • Osel, Inc.
  • Yakult Honsha Co.
  • Second Genome
  • Synthetic Biologics, Inc.
  • Vedanta Biosciences
  • Du Pont De Nemours and Co.
  • Ferring Pharmaceuticals

Kindly go through and get access to our comprehensive coverage of myriad number of healthcare reports published in the last three months:

Recent Developments:

  • On Jan 7th 2022, Ferring Pharmaceuticals successfully launched its Ferring’s Microbiome Health Index, a promising tool that accurately measures disrupted gut microbiota after the subsequent gut microbiota restoration and antibiotic treatments. The Microbiome Health Index was developed by Ferring pharmaceuticals to manage the various risks that are associated with antibiotic administration & providing proper guidance for the development of live biotherapeutic products.
  • On Dec 9th 2021, 4D Pharma announced its new faecal microbiome analysis for the completion of the Phase II trial of Blautix (MRx1234) as a treatment for irritable bowel syndrome with diarrhoea (IBS-D) or constipation (IBS-C). The Phase II study was regarded as a randomized, multicentre & double-blind trial that enrolled around 353 patients suffering from IBS-C or IBS-D. The patients were treated for 8 weeks with either placebo or Blautix. Microbial Co-Occurrence and Microbiome composition network analysis were performed on approximately 949 faecal samples of four study treatment groups (IBS-C placebo-treated study, IBS-C Blautix-treated study, IBS-D placebo-treated study, IBS-D Blautix-treated study,) at baseline (week 0), mid-treatment (4th week), end of treatment (8th week), and wash-out (12th week) stages.

Related Reports:

Global DNA Sequencing Market Report

SMR’s ‘DNA Sequencing Market Report withInsights & Forecast 2030’ delivers a pellucid idea of the detailed market insights such as its driving factors, restraints, opportunities, etc. The Global DNA sequencing market in 2020 accounted for up to USD 9 billion. The market is likely to propel with a CAGR of 17.12% to nearly USD 44 billion by 2030. Key factors that are fuelling the market growth continuously are the Increasing Application in Clinical Diagnosis, Technological Advancements in DNA sequencing, & Drug Discovery. The key players that are involved in this market are Thermo Fischer Scientific, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., F. Hoffman-La Roche Ltd., Pacific Biosciences, Siemens Healthineers AG, etc.

Global Live Cell Imaging Market Report

SMR’s ‘Live Cell Imaging Market Report Insights & Forecast 2030’ caters to an excellent concept of the pivotal market insights like restraints, drivers, future opportunities, etc. In 2020, the Global live-cell imaging Market size was valued at around USD 1.8 billion, & the market is predicted to grow at a CAGR of nearly 8.8%, thereby reaching a landmark of around USD 4.18 billion by 2030. A steep surge in the adoption rate of high content screening in drug discovery and the continuous rise of chronic or NCD diseases are driving the market growth forward. The pivotal organizations that are associated with it are Carl Zeiss AG, Nikon Corporation, Danaher Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Olympus Corporation, Thermo Fisher Scientific Inc., Oxford Instruments, BioTek Instruments, Sartorius AG, Etaluma Inc., CytoSMART Technologies.

Global Recombinant Protein Market Report

SMR’s ‘Recombinant Protein Market’ ReportInsights & Forecast 2030’ highlights a clear concept regarding the key market insights like drivers, restraining factors, opportunities, etc. The Global Recombinant Protein Market size was valued at up to USD 1.5 billion in 2020, & it’s expected to prosper at a CAGR of around 10.12% from 2020 to 2030. As a result, by 2030, the market is expected to reach a benchmark of around USD 3.93 billion. The key factors that are expediting the market growth are a rise in the government funding for R&D activities, the growing prevalence of chronic diseases, an increase in the number of regulatory approvals, and the need to reduce viral infections. The key companies that are associated with this market are Thermo Fisher Scientific, Inc., Abcam plc, Merck KGaA, Proteintech Group, Inc., Janssen-Cilag Pty Ltd., etc.

Global Blood Transfusion Market Report

SMR’s ‘Blood Transfusion Market Report Insights & Forecast 2030’ elucidates a 360-degree picture of the essential market insights like drivers, restraints, opportunities, etc. In 2020, the Blood transfusion market accounted for up to USD 6.7 billion. It is poised to reach a benchmark of USD 9.6 billion by 2028, with a promising CAGR of 6 % throughout the forecasted period. The continuous increase in the number of surgical operations, rapid technological advancements, and rise in the number of accidents are some of the major factors that are accelerating the growth rate of the blood transfusion market. Also, the key players that are associated with this market are Becton Dickinson, Haemonetics Corporation, B. Braun Melsungen AG, Kaneka Corporation, Grifols SA, Macopharma SA, Fresenius Kabi, Terumo Corporation, Immucor Inc.

Global Hemostats and Tissue Sealants Market Report

SMR’s ‘Hemostats and Tissue Sealants Market Report Insights & Forecast 2030’ delineates an overall idea regarding the crucial insights of the market, such as drivers, restraints, opportunities, etc. In 2020, the Global Hemostats & Tissue Sealants Market accounted for up to USD 6.35 billion. The market is poised to reach around USD 11.27 billion by 2028, projecting a CAGR value of nearly 8.93 %. The vital factors that are accelerating the market growth are the introduction of Fibrin Sealant Products & the rise of applications in the drug delivery mechanisms. Apart from that, the key players associated with this market are Baxter, Advanced Medical Solutions Group plc, Cohera Medical Inc, CryoLife Inc, C.R. Bard Inc, Integra Life Sciences Corporation, Johnson & Johnson Services Inc, Pfizer Inc, B Braun Medical Inc, Cohesion Technologies Inc, etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Press Release:

Connect Us: